Cyclophosphamide (CP) is an important anticancer drug which belongs to the class of
alkylating agent. Cyclophosphamide is mostly used in bone marrow transplantation …

Background The dose-limiting toxic effect of cyclophosphamide (CY) is cardiotoxicity. The
pathogenesis of myocardial damage is poorly understood, and there is no established …

Introduction Cyclophosphamide (CP) causes redox imbalance and its use is associated with
marked cardiotoxicity that limits its clinical applications. The present study investigated the …

Anthracycline‐induced cardiotoxicity (AIC) persists as a significant cause of morbidity and
mortality in cancer survivors. Although many protective strategies have been evaluated …

Cyclophosphamide (CP), one of the most widely prescribed antineoplastic drugs could
cause a lethal cardiotoxicity. The present study is aimed at evaluating the role of dl-α-lipoic …

Cyclophosphamide (CP), an alkylating agent widely used in cancer chemotherapy, causes
fatal cardiotoxicity. In the present study, lupeol, a pentacyclic triterpene, isolated from …

Cyclophosphamide (CP) is an oxazaphosphorine nitrogen mustard alkylating drug used for
the treatment of chronic and acute leukemias, lymphoma, myeloma, and cancers of the …

Introduction Cyclophosphamide (CP) is a potent anticancer agent; its clinical use is limited
due to its marked cardiotoxicity. Aim The present study was aimed at evaluating the …

Anthracyclines are a class of highly potent antitumor antibiotics utilized against hematologic
and solid tumors in children and in adults. Their use has been limited primarily by their …

The chemotherapeutic and immunosuppressive agent cyclophosphamide has previously
been shown to induce complications within the setting of bone marrow transplantation. More …